Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788120 | 0.87 | HDAC6 (0.37) | MAPTHDAC6KMT2ATP53NPC1 | |
| SCHEMBL1787825 | 0.82 | MAPT (0.39) | MAPTHDAC6KMT2ATP53 | |
| SCHEMBL1789608 | 0.82 | NAMPT (0.49) | ROCK2MAPTHDAC6KMT2ANPC1 | |
| SCHEMBL1787706 | 0.81 | HDAC6 (0.43) | HDAC6KMT2ATP53NPC1RAB9A | |
| SCHEMBL1789970 | 0.80 | ROCK2 (0.49) | ROCK2MAPTHDAC6KMT2ATP53 | |
| SCHEMBL1787644 | 0.80 | ALDH1A1 (0.53) | MAPTKMT2ATP53NPC1RAB9A | |
| SCHEMBL1787617 | 0.80 | HRH3 (0.49) | ROCK2MAPTHDAC6 | |
| SCHEMBL1790327 | 0.80 | GAA (0.48) | ROCK2MAPTTP53 | |
| SCHEMBL1790098 | 0.80 | MAPT (0.48) | MAPTHDAC6KMT2ATP53DRD2 | |
| SCHEMBL1789725 | 0.79 | EPHX2 (0.48) | MAPTHDAC6KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | ROCK2 2377/4885MAPT 3598/4885HDAC6 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.